The NeurologyLive® Narcolepsy Disease Spotlight page offers specific updates and coverage on the latest expert conversations and data readouts related to the treatment and management of patients with the sleep disorder.
May 8th 2024
Alberto Ramos, MD, FAAN, director of the Sleep Disorders program at the University of Miami, provided commentary on a session chaired at AAN 2024 assessing the diagnostic criteria and treatment options of parasomnias in adults.
Narcolepsy Potentially Identified as a Symptom of Immediate Food Allergic Reactions in Pediatrics
September 20th 2023In a large cohort of 848 pediatric participants with challenge-proven food allergy, investigators identified narcolepsy-like sleepiness as a symptom impacting more than 1 in 10 patients with food allergies.
Long-Term Safety and Tolerability of Low-Sodium Oxybate Confirmed
September 19th 2023In a recent long-term analysis of a phase 3 trial, the most common treatment-emergent adverse events that led to discontinuation of low-sodium oxybate were cataplexy, headache, nausea, and psychiatric disorders.
Ulotaront Fails to Differentiate From Placebo in Phase 1b Crossover Trial for Narcolepsy-Cataplexy
September 17th 2023Acute and sustained treatment with ulotaront did not show a statistically significant decrease from placebo in total number of cataplexy events and had no significant change in other symptomatic ratings over a 2-week treatment period.
Opioids Improve Disturbed Nocturnal Sleep and Excessive Daytime Sleepiness in Narcolepsy Type 1
September 14th 2023In a recent study on patients with narcolepsy type 1, those who used opioid drugs such as oxycodone and codeine were significantly associated with improved self-reported narcolepsy symptom severity.
Longer Sleep Latency Time Observed With Recent Definition of Sleep Onset, Meta-Analysis Shows
September 14th 2023A recent systematic review and meta-analysis showed that normal mean sleep latency in adults was 11.7 minutes using the earlier definition of sleep onset and 11.8 minutes using the later definition of sleep onset.
Significantly Larger Hypothalamic Volume in Narcolepsy Type 1 Following H1N1 Infection
August 11th 2023Prior research shows that a significant loss of the hypocretin-producing neurons, an increase in the histaminergic neurons, and contradicting signs of gliosis in the hypothalamus among patients with narcolepsy type 1.
Increased New-Onset Cardiovascular Risk Observed in Narcolepsy
July 28th 2023The findings confirmed and expanded upon existing literature by demonstrating that the incidence rates of multiple cardiovascular events, including stroke, heart failure, and cardiovascular disease, are significantly higher in patients with narcolepsy.
How Once-Nightly Sodium Oxybate Changes the Treatment Landscape for Narcolepsy
June 9th 2023John Harsh, PhD, clinical research director, Colorado Sleep Institute, sat down at SLEEP 2023 to discuss the RESTORE study results, and why patients with narcolepsy appear to prefer once-nightly sodium oxybate.
Samelisant Shows Potential as a Treatment for Excessive Daytime Sleepiness in Parkinson Disease
June 7th 2023Preclinical findings show the potential of samelisant, a potent and orally active Histamine H3 receptor inverse agonist, as a potential treatment for patients with Parkinson disease who experience excessive daytime sleepiness.
Enrollment for Phase 3 INTUNE Study of Pitolisant in Idiopathic Hypersomnia Ahead of Schedule
May 29th 2023Pitolisant, a therapy approved for patients with narcolepsy, is currently being assessed in 200 individuals with idiopathic hypersomnia, with change in excessive daytime sleepiness as the primary outcome.
Expanding KP1077’s Clinical Program to Address Narcolepsy and Other Conditions: Christal Mickle
April 21st 2023The cofounder and chief product development officer of Zevra Therapeutics talked about the phase 1 clinical trial of KP1077 for narcolepsy and potentially using it to treat other conditions. [WATCH TIME: 5 minutes]